Compounding Pharmacy Market Size, Growth, Share & Trends Analysis
Compounding Pharmacy Market by Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT), Sterility (Sterile), End User (Pediatric, Adult) - Global forecast to 2030
USD 19.41
MARKET SIZE, 2030
CAGR 5.7%
(2025-2030)
350
REPORT PAGES
480
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The compounding pharmacy market is projected to reach USD 19.41 billion by 2030 from USD 14.72 billion in 2025, at a CAGR of 5.7% from 2025 to 2030. A compounding pharmacy is a practice in which a licensed pharmacist combines, mixes, or alters the ingredients of a drug to create a medication tailored to the needs of an individual patient. Its market growth is fueled by persistent drug shortages in North America and Europe and continued supply gap for GLP-1 drugs to enhance compounding pharmacy revenues.
KEY TAKEAWAYS
-
BY PRODUCTThe compounding pharmacy market comprises topical drugs, oral drugs, parenteral drugs, rectal drugs, nasal drugs, ophthalmic drugs, and other products. Oral drugs are used widely because they are customized for patient-specific therapies that address individual medical needs.
-
BY COMPOUNDING TYPEIt includes pharmaceutical ingredient alteration, currently unavailable pharmaceutical manufacturing, and pharmaceutical dosage alterations. Pharmaceutical dosage alteration dominates the compounding pharmacy market as it addresses the widespread need for patient-specific doses, strengths, and forms that are not commercially available.
-
BY THERAPEUTIC APPLICATIONTherapeutic applications include pain management, hormone replacement therapy, dermal disorders, nutritional supplements, and other applications. Pain management dominates the compounding pharmacy market due to the high prevalence of chronic and localized pain conditions that require customized formulations for effective treatment relief.
-
BY STERILITY TYPEIt includes sterile and non-sterile preparations, in which sterile preparations dominate the compounding pharmacy market.; this dominance is attributed to the increasing demand for injectable medications, parenteral nutrition, and advanced biologic therapies
-
BY END USERThe compounding pharmacy market is segmented into pediatrics, adults, and geriatrics. Adults represent the largest segment by end user. This dominance mainly results from the high rate of chronic conditions and lifestyle-related diseases among adults, which often require personalized medication solutions.
-
BY REGIONThe Asia Pacific is expected to grow fastest, driven by factors such as rapid healthcare infrastructure development, increasing disposable incomes, and a growing demand for personalized medicines.
-
COMPETITIVE LANDSCAPEThe major market players have adopted both organic and inorganic strategies, including partnerships and investments. For instance, Fagron and B. Braun Melsungen AG entered into agreements and partnerships to cater to the growing demand for compounding pharmacy across innovative applications.
The compounding pharmacy market is projected to grow rapidly over the next decade, supported by the full enforcement of USP standards, which boosts demand for compliant compounding services, and a safety push for ready-to-administer (RTA) and standardized doses. Compounding pharmacy is gaining momentum as a vital part of healthcare, providing customized medications tailored to individual patient needs that cannot be met by commercially available drugs. Growing demand for personalized treatments, management of rare conditions, and alternatives during drug shortages highlight its significance. By allowing flexibility in dosage forms, strengths, and formulations, compounding pharmacies are becoming a key element of patient-focused care, encouraging use across hospitals, specialty clinics, and community health settings.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on compounding pharmacies’ business stems from changing patient and healthcare provider trends. The market has seen major shifts that are likely to speed up during the forecast period. These include the increasing prevalence of chronic diseases, the greater use of personalized medicines with tailored dosage forms, rising demand for sterile compounding and biologics support, and growing interest in weight management and hormone replacement therapies. These short- and long-term trends are expected to alter demand patterns across hospitals, specialty clinics, and retail pharmacies, creating growth opportunities for compounding pharmacies and their suppliers.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Persistent drug shortages in North America and Europe
-
Full enforcement of USP standards boosts demand for compliant compounding services.
RESTRAINTS
Impact
Level
Level
-
Resolution of GLP-1 shortages reduces reliance on compounded alternatives
-
Stricter FDA oversight & Insanitary Conditions enforcement
OPPORTUNITIES
Impact
Level
Level
-
Radiopharmaceutical compounding standardization
-
Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic & chemo-adjuncts
CHALLENGES
Impact
Level
Level
-
Capacity bottlenecks in API, excipient supply, and CCI/testing
-
Limited quality-system maturity and gaps in stability/BUD evidence generation
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Persistent drug shortages in North America and Europe
Persistent drug shortages in North America and Europe are driving the growth of the compounding pharmacy market. As conventional manufacturers struggle to meet demand, healthcare providers increasingly rely on compounding pharmacies to supply customized, high-quality medications, ensuring continuity of care for adults, pediatrics, and geriatric patients across diverse therapeutic areas.
Restraint: Resolution of GLP-1 shortages reduces reliance on compounded alternatives
The resolution of GLP-1 drug shortages has reduced the reliance on compounded alternatives, restraining growth in the compounding pharmacy market. With commercial manufacturers now meeting demand, healthcare providers and patients increasingly access standard formulations, limiting the need for customized compounding solutions across adults, pediatrics, and geriatric populations.
Opportunity: Radiopharmaceutical compounding standardization
Standardizing radiopharmaceutical compounding offers a major opportunity in the compounding pharmacy market. Applying consistent protocols and quality standards improves safety, effectiveness, and regulatory adherence. This enables pharmacies to efficiently produce personalized radiopharmaceuticals for adults, pediatrics, and geriatric patients, increasing adoption in hospitals, specialty clinics, and nuclear medicine facilities.
Challenge: Capacity bottlenecks in API, excipient supply, and CCI/testing
Capacity bottlenecks in API, excipient supply, and CCI/testing present a key challenge for the compounding pharmacy market. Limited availability of high-quality raw materials and restricted testing capabilities slow down the production of customized medications, affecting timely delivery to adults, pediatrics, and geriatric patients, and could impact overall market growth and service reliability.
Compounding Pharmacy Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Specializes in Bioidentical Hormone Replacement Therapy (BHRT) for menopause and hormonal imbalances | Personalized hormone formulations (creams, gels, capsules) based on lab results |
 |
Creates custom pain creams combining NSAIDs, anesthetics, and muscle relaxants | Tailored topical treatments for chronic pain and neuropathy; avoids systemic side effects |
 |
Compounds veterinary and human medications, including hormone therapies and dermatological treatments | Offers niche formulations not available commercially; supports individualized care |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The compounding pharmacy ecosystem comprises interconnected relationships among various stakeholders, including raw material suppliers, compounding pharmacies, contract compounding organizations (CCOs), distributors, and end users. Raw material suppliers provide essential components such as active pharmaceutical ingredients (APIs), excipients, sterile and non-sterile bases, and specialized chemicals to compounding pharmacies. These pharmacies use customized formulations and compounding technologies to create patient-specific medications, including oral, topical, injectable, and parenteral products. CCOs and specialized service providers support scale-up, quality assurance, and regulatory compliance. Distributors and supply partners facilitate the delivery of compounded medications to end users, including pediatric, adult, and geriatric populations, thereby optimizing the supply chain. This integrated ecosystem improves operational efficiency, ensures personalized therapeutic solutions, and promotes the growth and commercialization of compounded medications across diverse therapeutic areas.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
compounding pharmacy Market, By Product
In 2024, oral drugs held the highest share in the compounding pharmacy market due to the Customization of dosage, flavor, and release profiles, which improves patient adherence. Growing chronic disease prevalence and advances in formulation technologies support market growth.
Compounding pharmacy Market, By Compounding Type
In 2024, pharmaceutical dosage alteration accounted for the highest share by compounding type, driven by the need for personalized dosing, patient-specific formulations, improved adherence, and flexibility across pediatric, adult, and geriatric populations.
compounding pharmacy Market, By Therapeutic Applications
In 2024, pain management held the highest share by therapeutic area in the compounding pharmacy market, driven by rising chronic pain prevalence, increasing demand for personalized therapies, and the growing adoption of customized topical and oral formulations.
Gene delivery technology Market, By Sterility
In 2024, sterile compounding dominated the compounding pharmacy market due to the increasing demand for injectable medications, parenteral nutrition, and advanced biologic therapy.
compounding pharmacy Market, By End User
Adults segment held the highest share by end user in 2024; this trend is linked to the increasing rate of chronic conditions among adults, requiring tailored treatment options.
REGION
Asia Pacific to be fastest-growing region in global compounding pharmacy market during forecast period
In 2024, the Asia Pacific region is the fastest-growing market for compounding pharmacies, driven by rising healthcare awareness, increasing prevalence of chronic diseases, expanding geriatric and pediatric populations, and growing adoption of personalized medications. Supportive government initiatives, improved healthcare infrastructure, and the presence of skilled pharmacists further fuel growth in the region.
Compounding Pharmacy Market: COMPANY EVALUATION MATRIX
In the compounding pharmacy market matrix, Empower Pharmacy (Star Player) leads with a strong market presence, an extensive portfolio of sterile and non-sterile compounded medications, and a robust distribution network, driving widespread adoption across hospitals, clinics, and specialty care centers. Quva (Emerging Leader) is gaining traction with personalized formulations, innovative compounding services, and expanding reach in niche therapeutic areas. Meanwhile, companies such as Baxter dominate in manufacturing scale, while smaller players such as Fusion Apothecary show strong growth potential to advance toward the leaders’ quadrant
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USS 13.48 Billion |
| Market Forecast in 2030 (Value) | USS 19.41 Billion |
| Growth Rate | CAGR of 5.7% from 2025-2030 |
| Years Considered | 2022-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
WHAT IS IN IT FOR YOU: Compounding Pharmacy Market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Formulation Insights | Analysis of dosage forms (e.g., topical, oral, injectable) and excipient compatibility | Helps pharmacists optimize stability, bioavailability, and patient compliance |
| Regulatory & Compliance Overview | Summary of FDA 503A/503B guidelines, USP standards, and state-specific regulations | Ensures legal compliance and supports audit readiness |
| Technology Comparison | Comparison of compounding vs. commercial alternatives in terms of cost, efficacy, and access | Informs strategic decisions on service offerings and pricing |
RECENT DEVELOPMENTS
- February 2024 : Fagron acquired University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder specializing in the health and wellness segment in California. This acquisition enhances Fagron’s national footprint in the U.S., complementing its existing 503A and 503B operations and expanding its offerings in hormone and urology treatments.
- February 2024 : Empower Pharma acquired Eugia US Manufacturing LLC's manufacturing facility in East Windsor, New Jersey. This acquisition expands Empower Pharma's sterile development and bulk manufacturing capabilities for personalized compounded medicine.
- September 2022 : Walgreens acquired Shields Health Solutions, a leader in hospital and health system specialty pharmacy services. This acquisition bolstered Walgreens' position in the compounding pharmacy market, particularly in providing specialized medications to hospital patients
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
31
2
RESEARCH METHODOLOGY
35
3
EXECUTIVE SUMMARY
48
4
PREMIUM INSIGHTS
54
5
MARKET OVERVIEW
Market shifts drive demand for RTA doses amid persistent drug shortages and regulatory pressures.
60
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
PERSISTENT DRUG SHORTAGES IN NORTH AMERICA AND EUROPE
5.2.1.2
ENFORCEMENT OF USP STANDARDS
5.2.1.3
PUSH FOR READY-TO-ADMINISTER (RTA) AND STANDARDIZED DOSES
5.2.1.4
CONTINUED DEMAND-SUPPLY GAP FOR GLP-1 DRUGS
5.2.1.5
TREND TOWARDS PERSONALIZATION OF DOSES
5.2.2
RESTRAINTS
5.2.2.1
RESOLUTION OF GLP-1 SHORTAGES AND REDUCED RELIANCE ON COMPOUNDED ALTERNATIVES
5.2.2.2
STRICTER FDA OVERSIGHT AND INTENSIFIED ENFORCEMENT OF UNSANITARY CONDITIONS VIOLATIONS
5.2.2.3
LIMITATIONS ON BULK DRUG SUBSTANCES
5.2.3
OPPORTUNITIES
5.2.3.1
EXPANSION OF HOSPITAL OUTSOURCING INTO ANESTHESIA, CRITICAL CARE, OPHTHALMIC, AND CHEMO-ADJUNCTS
5.2.3.2
RADIOPHARMACEUTICAL COMPOUNDING STANDARDIZATION
5.2.4
CHALLENGES
5.2.4.1
CAPACITY BOTTLENECKS IN API, EXCIPIENT SUPPLY, AND CRITICAL COMPOUNDING INFRASTRUCTURE TESTING
5.2.4.2
LIMITED QUALITY-SYSTEM MATURITY AND GAPS IN STABILITY/BUD EVIDENCE GENERATION
5.3
PORTER’S FIVE FORCES ANALYSIS
5.3.1
THREAT OF NEW ENTRANTS
5.3.2
THREAT OF SUBSTITUTES
5.3.3
BARGAINING POWER OF SUPPLIERS
5.3.4
BARGAINING POWER OF BUYERS
5.3.5
INTENSITY OF COMPETITIVE RIVALRY
5.4
KEY STAKEHOLDERS & BUYING CRITERIA
5.4.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.4.2
KEY BUYING CRITERIA
5.5
MACROECONOMICS INDICATORS
5.5.1
HEALTHCARE EXPENDITURE TRENDS
5.5.2
GLOBAL CANCER BURDEN
5.5.3
IMPACT OF PHARMA R&D
5.6
VALUE CHAIN ANALYSIS
5.7
ECOSYSTEM ANALYSIS
5.7.1
ROLE IN ECOSYSTEM
5.8
PRICING ANALYSIS
5.8.1
INDICATIVE PRICING ANALYSIS OF COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2024
5.8.2
INDICATIVE PRICING ANAYLSIS OF COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2024
5.9
KEY CONFERENCES & EVENTS, 2025–2026
5.10
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.11
INVESTMENT & FUNDING SCENARIO
5.12
TECHNOLOGY ANALYSIS
5.12.1
KEY TECHNOLOGIES
5.12.1.1
AUTOMATED COMPOUNDING DEVICES
5.12.1.2
STERILE COMPOUNDING EQUIPMENT
5.12.2
COMPLEMENTARY TECHNOLOGIES
5.12.2.1
QUALITY CONTROL & TESTING SYSTEMS
5.12.2.2
PHARMACY INFORMATION MANAGEMENT SOFTWARE (PIMS)
5.12.3
ADJACENT TECHNOLOGIES
5.12.3.1
3D PRINTING OF PHARMACEUTICALS
5.12.3.2
PERSONALIZED MEDICINE PLATFORMS
5.13
IMPACT OF AI/GEN AI ON COMPOUNDING PHARMACY MARKET
5.14
REGULATORY ANALYSIS
5.14.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
5.14.2
REGULATORY FRAMEWORK
5.15
IMPACT OF 2025 US TARIFF ON COMPOUNDING PHARMACY MARKET
5.15.1
INTRODUCTION
5.15.2
KEY TARIFF RATES
5.15.3
PRICE IMPACT ANALYSIS
5.15.4
IMPACT ON COUNTRY/REGION
5.15.4.1
US
5.15.4.2
EUROPE
5.15.4.3
ASIA PACIFIC
5.15.4.4
REST OF THE WORLD
5.15.5
IMPACT ON MANUFACTURING INDUSTRIES
5.16
UNMET NEEDS & WHITE SPACES
6
COMPOUNDING PHARMACY MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 43 Data Tables
98
6.1
INTRODUCTION
6.2
ORAL DRUGS
6.2.1
INCREASING DEMAND FOR PRECISE AND CUSTOMIZABLE ORAL FORMULATIONS IN UNMET PATIENT POPULATIONS TO DRIVE MARKET
6.3
TOPICAL DRUGS
6.3.1
RISING DEMAND FOR PERSONALIZED TOPICAL TREATMENTS AND ADVANCED DELIVERY VEHICLES TO FUEL MARKET GROWTH
6.4
PARENTERAL DRUGS
6.4.1
RISING DEMAND FOR STERILE INJECTABLE THERAPIES AND SUPPLY-CHAIN DISRUPTIONS TO BOOST MARKET GROWTH
6.5
OPTHALMIC DRUGS
6.5.1
RISING CASES OF EYE-RELATED DISORDERS TO ACCELERATE MARKET GROWTH
6.6
NASAL DRUGS
6.6.1
ADVANCEMENTS IN NASAL DRUG DELIVERY SYSTEMS AND FAVORABLE REGULATORY POLICIES TO PROPEL MARKET GROWTH
6.7
RECTAL DRUGS
6.7.1
PERSONALIZED FORMULATIONS AND REGULATORY SUPPORT TO DRIVE GROWTH IN RECTAL COMPOUNDING THERAPIES
6.8
OTHER PRODUCTS
7
COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
121
7.1
INTRODUCTION
7.2
PHARMACEUTICAL DOSAGE ALTERATION
7.2.1
TAILORED DOSAGE FORMS TO ENHANCE PATIENT ADHERENCE AND CUSTOMIZATION IN COMPOUNDED MEDICATIONS
7.3
PHARMACEUTICAL INGREDIENTS ALTERATION
7.3.1
INCREASED NEED FOR CUSTOMIZED PHARMACEUTICAL INGREDIENTS TO ENHANCE PATIENT-CENTRIC COMPOUNDING SOLUTIONS
7.4
CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING
7.4.1
PERSISTENT GLOBAL DRUG SHORTAGES AND LIMITATIONS OF LARGE-SCALE PHARMACEUTICAL PRODUCTION TO PROPEL ADOPTION
8
COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 31 Data Tables
132
8.1
INTRODUCTION
8.2
PAIN MANAGEMENT
8.2.1
NEED FOR PERSONALIZED PAIN RELIEF SOLUTIONS FOR CHRONIC AILMENTS TO SUPPORT MARKET
8.3
HORMONE REPLACEMENT THERAPIES
8.3.1
POPULARITY OF PERSONALIZED HORMONE THERAPIES TO DRIVE STEADY GROWTH IN GLOBAL COMPOUNDING PHARMACY MARKET
8.4
DERMAL DISORDERS
8.4.1
CUSTOMIZED DERMATOLOGICAL SOLUTIONS TO PROPEL GLOBAL COMPOUNDING PHARMACY MARKET EXPANSION
8.5
NUTRITIONAL SUPPLEMENTS
8.5.1
PERSONALIZED NUTRACEUTICALS TO OFFER NICHE BUT BETTER GROWTH OPPORTUNITIES IN COMPOUNDING PHARMACIES
8.6
OTHER THERAPEUTIC APPLICATIONS
9
COMPOUNDING PHARMACY MARKET, BY STERILITY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 13 Data Tables
149
9.1
INTRODUCTION
9.2
STERILE
9.2.1
RTU/RTA STERILE PREPARATIONS AND OPHTHALMIC PACKS TO DRIVE RAPID GROWTH IN COMPOUNDING PHARMACIES
9.3
NON-STERILE
9.3.1
503A/MAGISTRAL NON-STERILE PREPARATIONS TO DRIVE GLOBAL VOLUME AND VALUE LEADERSHIP IN COMPOUNDING PHARMACIES
10
COMPOUNDING PHARMACY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
157
10.1
INTRODUCTION
10.2
ADULTS
10.2.1
RISING CHRONIC DISEASE BURDEN AND PERSONALIZED THERAPIES TO AUGMENT ADULT SEGMENT GROWTH
10.3
GERIATRIC PATIENTS
10.3.1
AGING DEMOGRAPHICS AND DOSE-FORM CUSTOMIZATION TO PROPEL GERIATRIC SEGMENT GROWTH
10.4
PEDIATRIC PATIENTS
10.4.1
CUSTOMIZED DOSAGE FORMS AND PEDIATRIC-SPECIFIC NEEDS TO DRIVE GROWTH
11
COMPOUNDING PHARMACY MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 14 Countries | 131 Data Tables.
168
11.1
INTRODUCTION
11.2
NORTH AMERICA
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2
US
11.2.2.1
US TO DOMINATE NORTH AMERICAN COMPOUNDING PHARMACY MARKET DURING FORECAST PERIOD
11.2.3
CANADA
11.2.3.1
PERSONALIZED TREATMENTS, REGULATORY REINFORCEMENT, AND SUPPLY-GAP FILLING TO FUEL GLOBAL COMPOUNDING PHARMACY GROWTH
11.3
EUROPE
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2
GERMANY
11.3.2.1
AGING DEMOGRAPHICS, TECHNOLOGICAL ADVANCEMENTS, AND SUPPORTIVE REGULATIONS TO DRIVE MARKET
11.3.3
UK
11.3.3.1
PERSONALIZED TREATMENTS, CHRONIC DISEASE MANAGEMENT, AND REGULATORY SUPPORT TO SUPPORT MARKET GROWTH
11.3.4
FRANCE
11.3.4.1
FOCUS ON CHRONIC DISEASE MANAGEMENT TO FUEL GROWTH IN FRENCH COMPOUNDING PHARMACY MARKET
11.3.5
ITALY
11.3.5.1
RISING COMMERCIAL DRUG DEVELOPMENT PIPELINE TO SPUR MARKET GROWTH
11.3.6
SPAIN
11.3.6.1
GLOBAL REGULATORY ADVANCEMENTS AND RISING R&D ACTIVITIES TO DRIVE MARKET
11.3.7
REST OF EUROPE
11.4
ASIA PACIFIC
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2
CHINA
11.4.2.1
LOW MANUFACTURING COST AND HIGH DEMAND FOR MEDICINES TO FAVOR MARKET GROWTH
11.4.3
JAPAN
11.4.3.1
INCREASING PREVALENCE OF CHRONIC DISEASES AND GROWING GERIATRIC POPULATION TO FUEL DEMAND FOR CUSTOMIZED MEDICATIONS
11.4.4
INDIA
11.4.4.1
INCREASING PHARMA R&D ACTIVITIES TO SUPPORT MARKET GROWTH
11.4.5
AUSTRALIA
11.4.5.1
INNOVATION IN CLINICAL PRACTICE AND REGULATORY SUPPORT TO ACCELERATE COMPOUNDING PHARMACY GROWTH
11.4.6
SOUTH KOREA
11.4.6.1
REGULATORY INNOVATION AND AUTOMATION TO FUEL SOUTH KOREAN COMPOUNDING PHARMACY MARKET GROWTH
11.4.7
REST OF ASIA PACIFIC
11.5
LATIN AMERICA
11.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2
BRAZIL
11.5.2.1
GROWING PHARMACY & BIOLOGICS MANUFACTURING SECTORS AND RISING R&D SEPNDING TO DRIVE MARKET
11.5.3
MEXICO
11.5.3.1
REGULATORY IMPROVEMENTS, HIGH CANCER RATES, AND ROBUST PHARMACEUTICAL INDUSTRY TO BOOST MARKET GROWTH
11.5.4
REST OF LATIN AMERICA
11.6
MIDDLE EAST & AFRICA
11.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.6.2
GCC COUNTRIES
11.6.2.1
RISING DEMAND FOR BIOLOGICS AND INCREASING PREVALENCE OF NON-COMMUNICABLE DISEASES TO PROPEL MARKET GROWTH
11.6.3
REST OF MIDDLE EAST & AFRICA
12
COMPETITIVE LANDSCAPE
Discover how key players and startups are reshaping the compounding pharmacy market landscape.
241
12.1
INTRODUCTION
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023−2025
12.3
REVENUE ANALYSIS, 2022–2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1
STARS
12.5.2
EMERGING LEADERS
12.5.3
PERVASIVE PLAYERS
12.5.4
PARTICIPANTS
12.5.5
COMPETITIVE BENCHMARKING: KEY PLAYERS, 2024
12.5.5.1
COMPANY FOOTPRINT
12.5.5.2
REGION FOOTPRINT
12.5.5.3
PRODUCT FOOTPRINT
12.5.5.4
THERAPEUTIC APPLICATION FOOTPRINT
12.5.5.5
STERILITY FOOTPRINT
12.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1
PROGRESSIVE COMPANIES
12.6.2
RESPONSIVE COMPANIES
12.6.3
DYNAMIC COMPANIES
12.6.4
STARTING BLOCKS
12.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1
DETAILED LIST OF KEY STARTUP/SMES
12.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
12.7
COMPANY VALUATION & FINANCIAL METRICS
12.7.1
FINANCIAL METRICS
12.7.2
COMPANY VALUATION
12.8
BRAND/PRODUCT COMPARISON
12.9
COMPETITIVE SCENARIO
12.9.1
PRODUCT LAUNCHES
12.9.2
DEALS
12.9.3
EXPANSIONS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
260
13.1
KEY PLAYERS
13.1.1
BAXTER
13.1.1.1
BUSINESS OVERVIEW
13.1.1.2
PRODUCTS OFFERED
13.1.1.3
RECENT DEVELOPMENTS
13.1.1.4
MNM VIEW
13.1.2
EMPOWER PHARMACY
13.1.3
B. BRAUN SE
13.1.4
FAGRON
13.1.5
QUVA PHARMA, INC.
13.1.6
SCA PHARMA
13.1.7
NEPHRON PHARMACEUTICALS
13.1.8
LEITERS HEALTH
13.1.9
ICON GROUP
13.1.10
ROSEWAY LABS
13.1.11
ITH PHARMA
13.1.12
PENCOL COMPOUNDING PHARMACY
13.1.13
FORMUL8
13.1.14
AURORA COMPOUNDING PHARMACY
13.2
OTHER PLAYERS
13.2.1
CUSTOM MED APOTHECARY
13.2.2
INSTITUTIONAL PHARMACY SOLUTIONS
13.2.3
FUSION APOTHECARY
13.2.4
INNOVATION COMPOUNDING PHARMACY
13.2.5
RX3 COMPOUNDING PHARMACY
13.2.6
DOUGHERTY’S PHARMACY, INC.
13.2.7
LORRAINE’S PHARMACY
13.2.8
WELLS PHARMA
13.2.9
OLYMPIA PHARMACY
13.2.10
FRESH THERAPEUTICS
13.2.11
MEDIOS AG
14
APPENDIX
297
14.1
DISCUSSION GUIDE
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
14.4
RELATED REPORTS
14.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
COMPOUNDING PHARMACY MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
TABLE 3
COMPOUNDING PHARMACY MARKET: RISK ANALYSIS
TABLE 4
COMPOUNDING PHARMACY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 5
COMPOUNDING PHARMACY MARKET: PORTER’S FIVE FORCES
TABLE 6
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPOUNDING PHARMACY PRODUCTS (%)
TABLE 7
KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER
TABLE 8
HEALTH EXPENDITURE AND FINANCING, 2015–2024 (% OF GDP)
TABLE 9
US: CANCER INCIDENCE, BY STATE (2024)
TABLE 10
COMPOUNDING PHARMACY MARKET: ROLE IN ECOSYSTEM
TABLE 11
INDICATIVE PRICING ANALYSIS COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2024
TABLE 12
INDICATIVE PRICING ANAYLSIS OF COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2024
TABLE 13
COMPOUNDING PHARMACY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
TABLE 14
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18
COUNTRY-WISE REGULATORY SCENARIO FOR COMPOUNDING PHARMACIES
TABLE 19
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 20
COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 21
COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 22
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 23
EUROPE: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 24
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 25
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 26
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 27
COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 28
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29
EUROPE: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 33
COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 34
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35
EUROPE: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 39
COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 40
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41
EUROPE: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 45
COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 46
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47
EUROPE: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 51
COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 52
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53
EUROPE: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 57
COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 58
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 63
COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 64
COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 65
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 67
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 70
COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 71
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72
EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 76
COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION, 2023–2030 (USD MILLION)
TABLE 77
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
EUROPE: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION, 2023–2030 (USD MILLION)
TABLE 82
COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 83
COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)
TABLE 84
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
EUROPE: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)
TABLE 89
COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 90
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91
EUROPE: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 95
COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 96
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
EUROPE: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 101
COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 102
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 103
EUROPE: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 107
COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 108
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 110
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 113
COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 114
STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 115
NORTH AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116
EUROPE: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117
ASIA PACIFIC: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118
LATIN AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
MIDDLE EAST & AFRICA: STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 120
NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 121
NORTH AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122
EUROPE: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123
ASIA PACIFIC: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124
LATIN AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125
MIDDLE EAST & AFRICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 126
COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 127
COMPOUNDING PHARMACY MARKET FOR ADULTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 128
NORTH AMERICA: COMPOUNDING PHARMACY MARKET ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129
EUROPE: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 132
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 133
COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 134
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135
EUROPE: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 137
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 139
COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 140
NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141
EUROPE: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143
LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 145
COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 146
NORTH AMERICA: KEY MACROINDICATORS
TABLE 147
NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 148
NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 149
NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 150
NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 151
NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 152
NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 153
US: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 154
US: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 155
US: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 156
US: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 157
US: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 158
CANADA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 159
CANADA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 160
CANADA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 161
CANADA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 162
CANADA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 163
EUROPE: KEY MACROINDICATORS
TABLE 164
EUROPE: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 165
EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 166
EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 167
EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 168
EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 169
EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 170
GERMANY: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 171
GERMANY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 172
GERMANY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 173
GERMANY: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 174
GERMANY: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 175
UK: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 176
UK: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 177
UK: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 178
UK: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 179
UK: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 180
FRANCE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 181
FRANCE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 182
FRANCE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 183
FRANCE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 184
FRANCE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 185
ITALY: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 186
ITALY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 187
ITALY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 188
ITALY: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 189
ITALY: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 190
SPAIN: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 191
SPAIN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 192
SPAIN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 193
SPAIN: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 194
SPAIN: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 195
REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 196
REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 197
REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 198
REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 199
REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 200
ASIA PACIFIC: KEY MACROINDICATORS
TABLE 201
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 203
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 204
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 205
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 206
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 207
CHINA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 208
CHINA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 209
CHINA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 210
CHINA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 211
CHINA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 212
JAPAN: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 213
JAPAN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 214
JAPAN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 215
JAPAN: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 216
JAPAN: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 217
INDIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 218
INDIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 219
INDIA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 220
INDIA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 221
INDIA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 222
AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 223
AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 224
AUSTRALIA : COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 225
AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 226
AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 227
SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 228
SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 229
SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 230
SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 231
SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 232
REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 233
REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 234
REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 235
REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 236
REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 237
LATIN AMERICA: KEY MACROINDICATORS
TABLE 238
LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 239
LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 240
LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 241
LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 242
LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 243
LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 244
BRAZIL: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 245
BRAZIL: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 246
BRAZIL: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 247
BRAZIL: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 248
BRAZIL: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 249
MEXICO: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 250
MEXICO: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 251
MEXICO: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 252
MEXICO: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 253
MEXICO: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 254
REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 255
REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 256
REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 257
REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 258
REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 259
MIDDLE EAST & AFRICA: KEY MACROINDICATORS
TABLE 260
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 261
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 262
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 263
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 264
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 265
MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 266
GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 267
GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 268
GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 269
GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 270
GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 271
REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 272
REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)
TABLE 273
REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)
TABLE 274
REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)
TABLE 275
REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 276
OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023–2025
TABLE 277
COMPOUNDING PHARMACY MARKET: DEGREE OF COMPETITION
TABLE 278
COMPOUNDING PHARMACY MARKET: REGION FOOTPRINT
TABLE 279
COMPOUNDING PHARMACY MARKET: PRODUCT FOOTPRINT
TABLE 280
COMPOUNDING PHARMACY MARKET: THERAPEUTIC APPLICATION FOOTPRINT
TABLE 281
COMPOUNDING PHARMACY MARKET: STERILITY FOOTPRINT
TABLE 282
COMPOUNDING PHARMACY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 283
COMPOUNDING PHARMACY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT, THERAPEUTIC APPLICATION, AND REGION, 2024
TABLE 284
COMPOUNDING PHARMACY MARKET: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025
TABLE 285
COMPOUNDING PHARMACY MARKET: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 286
COMPOUNDING PHARMACY MARKET: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 287
BAXTER: COMPANY OVERVIEW
TABLE 288
BAXTER: PRODUCTS OFFERED
TABLE 289
BAXTER: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025
TABLE 290
EMPOWER PHARMACY: COMPANY OVERVIEW
TABLE 291
EMPOWER PHARMACY: PRODUCTS OFFERED
TABLE 292
EMPOWER PHARMACY: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 293
B. BRAUN SE: COMPANY OVERVIEW
TABLE 294
B. BRAUN SE: PRODUCTS OFFERED
TABLE 295
B. BRAUN SE: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025
TABLE 296
FAGRON: COMPANY OVERVIEW
TABLE 297
FAGRON: PRODUCTS OFFERED
TABLE 298
FAGRON: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 299
QUVA PHARMA, INC.: COMPANY OVERVIEW
TABLE 300
QUVA PHARMA, INC.: PRODUCTS OFFERED
TABLE 301
SCA PHARMA: COMPANY OVERVIEW
TABLE 302
SCA PHARMA: PRODUCTS OFFERED
TABLE 303
SCA PHARMA: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 304
NEPHRON PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 305
NEPHRON PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 306
NEPHRON PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 307
LEITERS HEALTH: COMPANY OVERVIEW
TABLE 308
LEITERS HEALTH: PRODUCTS OFFERED
TABLE 309
LEITERS HEALTH: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 310
ICON GROUP: COMPANY OVERVIEW
TABLE 311
ICON GROUP: PRODUCTS OFFERED
TABLE 312
ICON GROUP: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 313
ROSEWAY LABS: COMPANY OVERVIEW
TABLE 314
ROSEWAY LABS: PRODUCTS OFFERED
TABLE 315
ROSEWAY LABS: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025
TABLE 316
ITH PHARMA: COMPANY OVERVIEW
TABLE 317
ITH PHARMA: PRODUCTS OFFERED
TABLE 318
PENCOL COMPOUNDING PHARMACY: COMPANY OVERVIEW
TABLE 319
PENCOL COMPOUNDING PHARMACY: PRODUCTS OFFERED
TABLE 320
FORMUL8: COMPANY OVERVIEW
TABLE 321
FORMUL8: PRODUCTS OFFERED
TABLE 322
AURORA COMPOUNDING PHARMACY: COMPANY OVERVIEW
TABLE 323
AURORA COMPOUNDING PHARMACY: PRODUCTS OFFERED
TABLE 324
CUSTOM MED APOTHECARY: COMPANY OVERVIEW
TABLE 325
INSTITUTIONAL PHARMACY SOLUTIONS: COMPANY OVERVIEW
TABLE 326
FUSION APOTHECARY: COMPANY OVERVIEW
TABLE 327
INNOVATION COMPOUNDING PHARMACY: COMPANY OVERVIEW
TABLE 328
RX3 COMPOUNDING PHARMACY: COMPANY OVERVIEW
TABLE 329
DOUGHERTY’S PHARMACY, INC.: COMPANY OVERVIEW
TABLE 330
LORRAINE’S PHARMACY: COMPANY OVERVIEW
TABLE 331
WELLS PHARMA: COMPANY OVERVIEW
TABLE 332
OLYMPIA PHARMACY: COMPANY OVERVIEW
TABLE 333
FRESH THERAPEUTICS: COMPANY OVERVIEW
TABLE 334
MEDIOS AG: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
COMPOUNDING PHARMACY MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
COMPOUNDING PHARMACY MARKET: YEARS CONSIDERED
FIGURE 3
COMPOUNDING PHARMACY MARKET: RESEARCH DESIGN
FIGURE 4
COMPOUNDING PHARMACY MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 5
COMPOUNDING PHARMACY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 6
COMPOUNDING PHARMACY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 7
COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)
FIGURE 8
REVENUE SHARE ANALYSIS OF BAXTER (2024)
FIGURE 9
COMPOUNDING PHARMACY MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 10
COMPOUNDING PHARMACY MARKET: TOP-DOWN APPROACH
FIGURE 11
COMPOUNDING PHARMACY MARKET: CAGR PROJECTIONS
FIGURE 12
COMPOUNDING PHARMACY MARKET: DATA TRIANGULATION
FIGURE 13
COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
FIGURE 14
COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 15
COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 16
COMPOUNDING PHARMACY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 17
REGIONAL SNAPSHOT OF COMPOUNDING PHARMACY MARKET
FIGURE 18
RISING TREND OF PERSONALISED MEDICINES TO PROPEL MARKET GROWTH
FIGURE 19
US AND 0RAL DRUGS SEGMENT TO COMMAND LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025
FIGURE 20
INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 21
EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD
FIGURE 22
COMPOUNDING PHARMACY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 23
TOTAL PRESCRIPTION DRUG SALES, 2023–2030 (USD BILLION)
FIGURE 24
COMPOUNDING PHARMACY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 25
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF KEY COMPOUNDING PHARMACY PRODUCTS
FIGURE 26
KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER
FIGURE 27
GLOBAL PHARMACEUTICAL R&D EXPENDITURE, 2023–2030 (USD BILLION)
FIGURE 28
COMPOUNDING PHARMACY MARKET: VALUE CHAIN ANALYSIS
FIGURE 29
COMPOUNDING PHARMACY MARKET: ECOSYSTEM MAP
FIGURE 30
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN COMPOUNDING PHARMACY MARKET
FIGURE 31
INVESTMENT AND NUMBER OF DEALS IN COMPOUNDING PHARMACY MARKET, 2023–2025 (USD MILLION)
FIGURE 32
COMPOUNDING PHARMACY MARKET: IMPACT OF AI/GEN AI
FIGURE 33
NORTH AMERICA: COMPOUNDING PHARMACY MARKET SNAPSHOT
FIGURE 34
ASIA PACIFIC: COMPOUNDING PHARMACY MARKET SNAPSHOT
FIGURE 35
REVENUE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2022–2024 (USD MILLION)
FIGURE 36
MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET (2024)
FIGURE 37
COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 38
COMPOUNDING PHARMACY MARKET: COMPANY FOOTPRINT
FIGURE 39
COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 40
EV/EBITDA OF KEY VENDORS
FIGURE 41
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 42
COMPOUNDING PHARMACY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 43
BAXTER: COMPANY SNAPSHOT (2024)
FIGURE 44
B. BRAUN SE: COMPANY SNAPSHOT (2024)
FIGURE 45
FAGRON: COMPANY SNAPSHOT (2024)
Methodology
This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global compounding pharmacy market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives of major market companies, and industry consultants, to obtain and verify critical qualitative and quantitative data and evaluate the market's growth prospects. The global market size estimated through secondary research was then validated and refined with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the compounding pharmacy market. The secondary sources used for this study include US Food and Drug Administration (FDA), American Pharmacists Association (APhA), International Academy of Compounding Pharmacists (IACP), National Community Pharmacists Association (NCPA), Parenteral Drug Association (PDA), American Society of Health-System Pharmacists (ASHP), Pharmacy Compounding Accreditation Board (PCAB), European Directorate for the Quality of Medicines & HealthCare (EDQM), European Medicines Agency (EMA), International Pharmaceutical Federation (FIP), Journal of Compounding & Specialty Pharmacy (JCSP), National Center for Biotechnology Information (NCBI), Pharmaceutical Research and Manufacturers of America (PhRMA), Pharma & Biopharma Outsourcing Association (PBOA), World Journal of Pharmaceutical Research (WJPR). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
After an initial assessment of the global compounding pharmacy market landscape through secondary research, comprehensive primary research was conducted. This included in-depth interviews with market experts from the demand side, such as stakeholders from pharmaceutical and biotechnology companies, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, including C-suite and senior executives, product managers, and marketing and sales leaders from leading manufacturers, distributors, and channel partners. The research covered six major regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. About 70% of the primary interviews involved supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand market dynamics comprehensively.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both bottom-up and top-down approaches were used to estimate and validate the total size of the compounding pharmacy market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- A list of the major global players operating in the compounding pharmacy market was generated.
- The revenues generated from their compounding pharmacy product have been determined through annual reports and secondary sources (including paid databases)
- The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
- All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.
Global Compounding Pharmacy Market Size: Bottom-up and Top-down Approach
Data Triangulation
After estimating the market size using the process described above, the total market was divided into several segments and subsegments. To finish the overall market analysis and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown methods were used where applicable. The data was triangulated by examining various factors and trends from both the demand and supply sides.
Market Definition
A compounding pharmacy is a practice in which a licensed pharmacist combines, mixes, or alters the ingredients of a drug to create a medication tailored to the needs of an individual patient.
Stakeholders
- Pharmaceutical and Biotechnology Companies
- Compounding Pharmacies
- Research and Consulting Firms
- Academic Medical Centers
- Government Regulatory and Research Organizations
- Quality Assurance and Accreditation Bodies
- Clinical Research Institutes
Report Objectives
- To define, describe, and forecast the compounding pharmacy market based on product, compounding type, therapeutic application, sterility, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 concerning individual growth trends, prospects, and contributions to the compounding pharmacy market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning five main regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global compounding pharmacy market and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product approvals and launches, expansions, agreements, and collaborations in the Compounding pharmacy market
- To benchmark players within the compounding pharmacy market using the company evaluation matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Compounding Pharmacy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Before You Go
Expand Beyond Compounding Pharmacy Market
Explore the top 20 industries influencing your market growth
Human and AI Powered Market Intelligence
Find Untapped Markets
Growth opportunities and latent adjacency in Compounding Pharmacy Market